The Search for New Anti-Cancer Drugs

Dr. Claude Labrie (2001, 2002 and 2005 Research Grants)

Cancer cells are good at surviving, partially because of their ability to adapt to stress. Dr. Labrie’s lab has shown that the protein AIbZIP, which is found in high numbers in prostate cancer cells, helps cancer cells adapt to stress. He and his team have created peptides that can prevent AIbZIP from doing its job – which could ultimately cause the death of the cells. He is now testing the ability of these peptides to infiltrate cancer cells and cause cancer cell death. The long term goal of this research is to turn these cancer cell killing peptides into new anticancer drugs.

Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.

Click here for news archive